A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia-Reference-Cited by-同舟云学术

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia

Published:2001-07 Issue:1 Volume:114 Page:111-113
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Mesa Ruben A.,Tefferi Ayalew,Elliott Michelle A.,Hoagland H. Clark,Call Timothy G.,Schroeder Georgene S.,Yoon Soo-Young,Li Chin-Yang,Gray Leigh A.,Margolin S.,Hook C. Christopher

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2001.02883.x/fullpdf

Reference12 articles.

1. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia;Barosi;British Journal of Haematology,1999

2. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone;Cain;International Journal of Immunopharmacology,1998

3. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system;Dupriez;Blood,1996

4. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level;Gurujeyalakshmi;American Journal of Physiology,1999

5. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis;Iyer;Journal of Pharmacology and Experimental Therapeutics,1999

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms;Experimental & Molecular Medicine;2022-03-14

2. Bone marrow niche dysregulation in myeloproliferative neoplasms;Haematologica;2020-04-02

3. Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms;British Journal of Haematology;2020-03-13

4. Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab;Blood;2019-09-05

5. Synthesis and photophysical properties of deuteration of pirfenidone;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2018-11